Pediatric Rheumatologist Explains Many New Updates to ACR’s Juvenile Idiopathic Arthritis Guidelines
The new draft guidelines favor earlier DMARD therapy with ‘much decreased reliance on glucocorticoids that have several side ...
After the first 6 months of disease-modifying antirheumatic drugs (DMARDs) use in patients with rheumatoid arthritis (RA), most very abnormal results newly seen in long-term routine laboratory ...
A scoping review published in Arthritis Care & Research compares existing recommendations for the use of disease-modifying anti-rheumatic drugs (DMARDs) in pregnancy and reproductive health for women ...
Juvenile idiopathic arthritis (JIA) encompasses a group of pediatric inflammatory arthritides that includes oligoarticular JIA, polyarticular JIA, systemic JIA, psoriatic JIA, and enthesitis-related ...
More than 80% of patients with newly diagnosed rheumatoid arthritis, who were using bridging therapy, successfully tapered ...
JAK inhibitors, a new class of tsDMARDs, have shown superior efficacy in RCTs for RA compared to other biologics. Real-world studies highlight JAK inhibitors' benefits in clinical disease activity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results